Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data from University of Tsukuba provide new insights into breast cancer
April 2nd, 2009
"WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT center dot Co-administration of proton pump inhibitors (PPIs) increases plasma methotrexate (MTX) concentration in cancer patients receiving high-dose MTX (HDMTX) therapy. center dot There is controversy as to whether or not co-administration of PPIs affects plasma MTX elimination in HDMTX therapy. center dot Inhibitory activity of PPIs on breast cancer resistance protein (BCRP) is a possible mechanism for the drug interaction between MTX and PPIs. WHAT THIS ADDS center dot Co-administration of a PPI (omeprazole, lansoprazole, or rabeprazole) was more frequently observed in the delayed MTX elimination group than in the normal MTX elimination group....
Source: Women's Health Weekly (2009-04-02)
|
